Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $81.9752W HIGH $135.13
Volume
13.91 M
Value Traded
608.40 M
Short % Float
1.16%
+1.02%Week
-6.41%1 Month
+4.85%3 Month
-1.8%6 Month
-26.07%5 Year
+52,988.69%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
170.43 B
EPS (TTM)
3.14
P/E Ratio
31.42
Ent. Value
197.43 B
Total Shares
1.73 B
Float Shares
1.72 B
Insiders
0.68%
Institutions
82.09%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ABT Catalyst Timeline
Dated clinical, regulatory and corporate events for Abbott Laboratories
Catalyst Timeline
Dated clinical, regulatory & corporate events for Abbott Laboratories
1446Total events
2Upcoming
557Tier-1 (high impact)
2010 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationPresentation
New research on Healthy Food Rx program presented at ADA 86th Scientific Sessions
type 2 diabetessource ↗
●NDA SubmissionRegulatory Filing
FDA regulatory submission for Libre Duo and Libre Duo 10 Day
diabetessource ↗
◆Oral PresentationPresentation
Pipeline Innovation abstract presentation at ASCO 2026
Pipeline Innovationsource ↗
◆Oral PresentationCancerguardPresentation
Cancerguard MCED test abstract presentation at ASCO 2026
Multi-Cancer Early Detectionsource ↗
◆Oral PresentationOncodetectPresentation
Oncodetect MRD test abstract presentation at ASCO 2026
Molecular Residual Diseasesource ↗
◆Oral PresentationPresentation
Oncotype DX Breast Recurrence Score test abstract presentation at ASCO 2026
Breast Cancersource ↗
◆Poster PresentationCologuardPresentation
Cologuard test abstract presentation at ASCO 2026 (online only)
Colorectal Cancer Screeningsource ↗
▲EU ApprovalEx-US Regulatory
CE Mark secured for Libre Duo dual glucose-ketone sensing system
diabetessource ↗
▲Other Regulator MilestoneEx-US Regulatory
Anvisa approval for Epic Max surgical valve
aortic valve stenosis or aortic valve insufficiencysource ↗
▲Other Regulator MilestoneEx-US Regulatory
CE Mark for Libre Duo and Libre Duo 10 Day
diabetessource ↗
▲FDA Filing AcceptedRegulatory Filing
FDA clearance for Ultreon 3.0 Software
coronary artery diseasesource ↗
◆Late-BreakerPresentation
Late-breaking presentation of 6-month results from FlexPulse IDE study at HRS 2026
complex atrial fibrillationsource ↗
◆Late-BreakerPresentation
Late-breaking presentation of 3-month results from ASCEND CSP IDE trial at HRS 2026
heart rhythm disorders requiring pacing/defibrillationsource ↗
◆Late-BreakerPresentation
Late-breaking presentation of 1-month results from LEAP2 first-in-human study at HRS 2026
heart rhythm disorders requiring pacingsource ↗
◆Late-BreakerPresentation
Late-breaking poster presentation of 6-month results from Volt CE Mark Extension Cohort at HRS 2026
atrial fibrillationsource ↗
◆Oral PresentationCancerguardPresentation
New data on multi-biomarker approach at AACR 2026
multi-cancer early detectionsource ↗
●Quarterly UpdateCorporate
Full-year 2026 guidance updated to reflect Exact Sciences acquisition
▲Product LaunchPost-Market
Expanded distribution of Ensure Max Protein 42g to major retailers
muscle healthsource ↗
▲Product LaunchPost-Market
Expanded distribution of Ensure Max Protein 2 in 1 Muscle Support to major retailers
muscle healthsource ↗
▲Partnership / LicenseCorporate
Abbott Precision Oncology portfolio integrated into Flatiron's OncoEMR platform
oncologysource ↗
▲Oral PresentationPresentation
Italian real-world study results presented at ATTD 2026
Type 2 diabetes with basal insulinsource ↗
▲Full ResultsClinical Data
Italian interventional study results presented at ATTD 2026
Type 2 diabetes on basal insulinsource ↗
●Oral PresentationPresentation
FreeDM2 study presented at ATTD 2026
Type 2 diabetes on basal insulinsource ↗
◆Oral PresentationAmuletPresentation
Late-breaking data presentation on Amulet device at AF Symposium
atrial fibrillationsource ↗
▲Oral PresentationPresentation
12-month data from VOLT-AF IDE presented at AF Symposium
atrial fibrillationsource ↗
▲Oral PresentationPresentation
6-month data from FOCALFLEX presented at AF Symposium
atrial fibrillationsource ↗
▲EU ApprovalEx-US Regulatory
CE Mark approval for TactiFlex Duo Ablation Catheter
atrial fibrillationsource ↗
▲First Patient DosedTrial
First successful commercial cases in EU after CE Mark
atrial fibrillationsource ↗
◆Oral PresentationPresentation
Abbott at CES 2026 Booth #8713 showcasing Libre Assist
diabetessource ↗
▲FDA ApprovalFDA Decision
FDA approval of Volt PFA System for atrial fibrillation
atrial fibrillationsource ↗
▲FDA ApprovalFDA Decision
FDA clearance for Amplatzer Piccolo Delivery System
patent ductus arteriosus (PDA) in premature infantssource ↗
▲EU ApprovalEx-US Regulatory
CE Mark for Amplatzer Piccolo Delivery System
patent ductus arteriosus (PDA) in premature infantssource ↗
▲Product LaunchLingoApprovedPost-Market
Lingo app now available for Android devices
over-the-counter continuous glucose monitoringsource ↗
▲Product LaunchPost-Market
Launch of Ensure Max Protein 2 in 1 Muscle Support shake
muscle healthsource ↗
●Oral PresentationLingoApprovedPresentation
Protein supplement consumption associated with less glycemic exposure presented at Obesity Week
metabolic healthsource ↗
▲Oral PresentationPresentation
Presentation of real-world data on protein shakes and glucose levels at Obesity Week
blood sugar managementsource ↗
●Oral PresentationLingoApprovedPresentation
Real-world glycemic effects observed with non-prescription real-time CGM presented at Diabetes Technology Meeting
metabolic healthsource ↗
●Quarterly UpdateCorporate
Abbott reaffirms full-year 2025 organic sales growth guidance of 7.5% to 8.0% (ex-COVID tests) and adjusted EPS guidance narrowed to $5.12-$5.18
Past FDA Catalysts and PDUFA Decisions
How ABT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2005-12-08 | Meridia (sibutramine hydrochloride) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C43 / 100
Pipeline Score
$373M
Pipeline Value
Not rated
Valuation Signal
5
Drugs Scored
-
rNPV / MCap
Top 30%
Large Pharma(rank 198 of 658)
Percentile Rank
Abbott Laboratories carries a moderate pipeline score (43/100), with $373M risk-adjusted pipeline value, led by Mebeverine+Simethicone in Functional Bowel Disorder (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mebeverine+Simethicone Small moleculeCompletedNCT05175131 | Functional Bowel Disorder | Phase 3 | COMPLETED | 465 | May 18, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every ABT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TactiFlex Duo Ablation Catheter | complex atrial fibrillation | 2026-04-25 | six-month data for the 188-patient FlexPulse IDE study show positive patient outcomesRead More | Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MCCOY JOHN A. JR.Officer (VICE PRESIDENT AND CONTROLLER) | Sell | -27 24,549 held | $109.54 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ABT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.4 % (-48.1 %) | 36.30 M | 400.00 K | 471.43% ( 330.00 K) |
ABT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ABT ranks across every disease it competes in
Competitive Position is a premium feature
See how ABT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialABT News
ABTAbbott hosts conference call for third-quarter earnings
Abbott will announce its third-quarter 2026 financial results on October 21, before market opening. Following the announcement, a live webcast of the earnings conference call will take place at 8 a.m. Central time. The call will be accessible through Abbott's Investor Relations website, with an archived version available later.
Read more →ABTAbbott declares 411th consecutive quarterly dividend
Abbott has announced a quarterly dividend of 63 cents per share, marking its 411th consecutive payment since 1924. The dividend will be payable on November 16, 2026, to shareholders recorded by October 15, 2026. Abbott has a strong history of increasing its dividend for 54 years and is part of the S&P 500 Dividend Aristocrats Index.
Read more →ABTFirst Canadian Commercial Use of Abbott's Volt™ Pulsed Field Ablation System Advances Minimally Invasive Atrial Fibrillation Care
Abbott has announced the first Canadian use of its Volt Pulsed Field Ablation System at the McGill University Health Centre for treating atrial fibrillation. This innovative system offers precise energy delivery with fewer catheter exchanges and reduced radiation exposure. The Volt system's integration with Abbott's EnSite X EP System enhances procedural efficiency and supports quicker recovery through conscious sedation.
Read more →ABTAbbott hosts conference call for second-quarter earnings
Abbott will announce its second-quarter 2026 financial results on July 16, prior to market opening. Following the announcement, a live webcast of the earnings conference call will be held at 8 a.m. Central time. The call will be accessible via Abbott's Investor Relations website, with an archived version available later.
Read more →ABTNew Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents
A new survey by Similac reveals that social media pressures are impacting Gen Z parents' perceptions of parenthood. In response, the brand has launched the 'Love Without Measure' initiative, aimed at promoting authentic portrayals of parenting and combating comparison culture. This effort seeks to support new parents in embracing their unique journeys.
Read more →ABTAbbott declares 410th consecutive quarterly dividend
Abbott has announced a quarterly dividend of 63 cents per share, marking its 410th consecutive payout since 1924. This dividend will be paid on August 17, 2026, to shareholders recorded by July 15, 2026. Abbott has a strong history of increasing dividends for 54 years and is recognized in the S&P 500 Dividend Aristocrats Index.
Read more →ABTNew research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers New research presented at the American Diabetes Association's 86th Scientific Sessions showed that adults living with type 2 diabetes participating...
Research presented at the American Diabetes Association's 86th Scientific Sessions indicates that Abbott's Healthy Food Rx program significantly improves health outcomes for adults with type 2 diabetes when paired with community health worker support. The study involved 284 participants who received healthy food boxes alongside coaching over six months. Key findings highlight advancements in diet, physical activity, and overall health, suggesting the effectiveness of combining healthy food access with robust personal support systems. These insights reinforce the value of community-centered approaches in managing chronic diseases.
Read more →ABTNew Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected ...
Abbott recently presented new findings at the American Diabetes Association's Scientific Sessions, highlighting the rising issue of diabetic ketoacidosis (DKA) among diabetes patients. The data indicates a significant increase in DKA-related hospitalizations across various age groups, emphasizing the need for better awareness and detection strategies. Abbott’s dual glucose-ketone monitoring technology aims to address these challenges by allowing for earlier detection of rising ketone levels. This technology is currently pending FDA clearance and could help reduce preventable hospitalizations for DKA.
Read more →ABTAbbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetesDeutschland - EnglishDeutschland - Deutsch
Abbott has received CE Mark approval for its innovative Libre Duo system, the first dual glucose and ketone sensing technology for diabetes management. This system allows continuous monitoring of glucose and ketone levels every minute, enhancing patient safety by providing real-time data. The launch of Libre Duo is set for select European markets later this year.
Read more →ABTACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
Abbott has been reaffirmed by the American Cancer Society as a leader in noninvasive colorectal cancer screening with its Cologuard and Cologuard Plus tests. These tests are recommended for adults aged 45 and older at average risk for colorectal cancer, emphasizing early detection and treatment. Abbott is also preparing to launch a blood-based test pending FDA approval, enhancing its screening portfolio.
Read more →ABTAbbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
Abbott has received CE Mark approval for its innovative dual glucose-ketone sensing technology, known as Libre Duo. This groundbreaking system allows continuous monitoring of both glucose and ketone levels, aiding in diabetes management and the prevention of diabetic ketoacidosis. The Libre Duo will be launched in select European countries later this year, marking a significant advancement in diabetes care.
Read more →ABTAbbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology...
Abbott (NYSE: ABT) is set to present 11 abstracts at the American Society of Clinical Oncology (ASCO) 2026, showcasing new evidence across cancer diagnostics. This includes advancements in tests such as the Cancerguard® Multi-Cancer Early Detection Test and the Oncodetect® Molecular Residual Disease Test. The presentations reflect Abbott's continuous efforts and innovations in the cancer care continuum, signifying their commitment to improving patient outcomes through advanced diagnostics.
Read more →ABTAbbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform
Abbott has received FDA clearance and CE Mark for its Ultreon 3.0 AI-powered imaging platform. This next-generation technology combines optical coherence tomography with AI to enhance coronary imaging during minimally invasive procedures. The platform aims to improve clinical decision-making and patient outcomes by providing real-time insights and detailed imaging of arterial blockages.
Read more →ABTAbbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field...
Abbott has presented new late-breaking clinical data at the Heart Rhythm Society 2026, showcasing its innovations in treating heart rhythm disorders. The findings include positive six-month outcomes from the FlexPulse IDE study for the TactiFlex Duo Ablation Catheter, as well as promising results from trials for the Volt PFA System and investigational CSP technologies. These results highlight Abbott's commitment to improving patient care with advanced therapies for complex atrial fibrillation and conducting pacing solutions. Overall, Abbott's portfolio appears to be evolving effectively in addressing various arrhythmias.
Read more →ABTIN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION -------------------------------------------------------x IN RE ABBOTT LABORATORIES INFANT FORMULA SHAREHOLDER DERIVATIVE LITIGATI
Abbott Laboratories is involved in a proposed settlement for consolidated derivative litigation concerning breaches of fiduciary duty and violations of federal securities laws. The settlement aims to resolve claims against certain directors and officers while maintaining governance reforms that enhance Abbott's internal oversight. A settlement hearing is set for June 4, 2026, where the court will assess the fairness of the proposed settlement and related attorney fees. The defendants continue to deny any wrongdoing but support the settlement to avoid further litigation costs and disruptions.
Read more →ABTNew data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
Abbott presented new data at the AACR Annual Meeting 2026 highlighting advancements in its Cancerguard® multi-cancer early detection test. The data showcases a multi-biomarker approach that enhances early-stage cancer detection. Additionally, the DETECT-A study, which demonstrated long-term outcomes for patients, received recognition for its significant contributions to the field.
Read more →ABT▼ -6%on this newsshared move
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
Abbott reported its first-quarter 2026 results, highlighting a successful acquisition of Exact Sciences, which is expected to enhance growth. The company anticipates a full-year sales growth of 6.5% to 7.5% and adjusted earnings per share between $5.38 and $5.58. Despite some challenges in the Nutrition segment, overall performance aligns with expectations.
Read more →ABTNew survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
A new survey by Abbott reveals that while 74% of U.S. adults believe chronic diseases are preventable, only 25% feel confident in managing their health. The survey indicates that confusion, information overload, and costs hinder health actions. Abbott emphasizes the importance of simple, consistent healthy habits and has partnered with Sesame Workshop to promote healthy routines for families.
Read more →ABTAbbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
Abbott has announced the integration of its Precision Oncology portfolio with Flatiron's OncoEMR platform, allowing oncology providers to order tests and receive results directly within their clinical workflow. This integration aims to streamline processes and improve patient care by providing access to a range of tests, including Oncotype DX and OncoExTra, across a network of over 1,600 cancer care centers. The initiative is designed to facilitate faster treatment decisions and reduce administrative burdens for clinicians.
Read more →ABTAbbott hosts conference call for first-quarter earnings
Abbott will release its first-quarter 2026 financial results on April 16, 2026, before the market opens. Following the announcement, a live webcast of the earnings conference call will take place at 8 a.m. Central time. Investors can access the call through Abbott's Investor Relations website, with an archived version available later.
Read more →About Abbott Laboratories
Headquarters100 ABBOTT PARK ROAD, ABBOTT PARK, IL, 60064-3500
Founded1888
BIOPHARMAWATCH ELITE PLUS
Trade the next ABT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime